LYEL
NASDAQLyell Immunopharma Inc.
Price$12.64+0.73 (+6.13%)
01:45 PM07:45 PM
News · 26 weeks52+240%
2025-12-282026-06-21
Mix2990d
- Insider13(45%)
- SEC Filings7(24%)
- Other7(24%)
- Analyst2(7%)
Latest news
25 items- INSIDERLarge owner Innovative Cellular Therapeutics Holdings Ltd disposed of 66,500 shares, decreasing direct ownership by 2% to 2,933,500 units (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERNew insider Innovative Cellular Therapeutics Holdings Ltd claimed ownership of 3,000,000 shares (SEC Form 3)3 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERPresident and CEO Seely Lynn sold $7,337 worth of shares (388 units at $18.91), decreasing direct ownership by 0.52% to 73,878 units (SEC Form 4) (tax withholding)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERChief Scientific Officer Lee Gary K. sold $2,460 worth of shares (130 units at $18.92), decreasing direct ownership by 0.72% to 17,808 units (SEC Form 4) (withholding obligation)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERChief Operating Officer Hill Stephen J. sold $1,684 worth of shares (89 units at $18.92), decreasing direct ownership by 0.49% to 17,894 units (SEC Form 4) (tax liability)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERVP, Corporate Controller Bulis Veronica Sanchez sold $4,103 worth of shares (217 units at $18.91), decreasing direct ownership by 1% to 15,420 units (SEC Form 4) (for withholding tax)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- SECSEC Form 8-K filed by Lyell Immunopharma Inc.8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
- INSIDERSEC Form 4 filed by Director Rieflin William Jl4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERSEC Form 4 filed by Director Ramachandra Sumant4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERSEC Form 4 filed by Director Nabel Elizabeth G4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERSEC Form 4 filed by Director Klausner Richard4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERSEC Form 4 filed by Director Friedman Cathy4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERSEC Form 4 filed by Director Brawley Otis W4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERSEC Form 4 filed by Director Bachleda Mark4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- PRLyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 CongressMore than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate of 97%No Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS, supporting outpatient administrationTranslational data support biological basis for durable responses, including enhanced memory potential of cytotoxic effector cells from CD62L+ enrichment, and CD19/CD20 dual-targeting to overcome low antigen expressionPiNACLE pivotal clinical trial in 3L+ setting data update expected in second half of 2026; pivotal data readout expected in mid-2027, with BLA submission to follow in the second half of 2027 SOUTH SAN FRANCISCO, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ
- PRLyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 ExpansionGastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxisThe maximum tolerated dose has not yet been determinedNo difference is observed in GCC CAR T-cell expansion kinetics in patients with or without GI prophylaxisOngoing U.S. Phase 1 trial amended to enable seamless expansion into a potential pivotal single-arm Phase 2 trial pending regulatory alignmentAmendment of ongoing U.S. Phase 1 trial adds new cohorts, including a second-line cohort and a cohort evaluating a combination strategy with radiotherapyAdditional Phase 1 clinical data, including clinical outcomes, and End-of-Phase 1 FDA meeting expected in second half of 2026 SOU
- PRLyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Monday, June 8, 2026, in Miami, Florida, with a fireside chat scheduled for 11:20 am Eastern Time. A live webcast of the fireside chat and subsequent replay can be accessed through the Investors section of the Company's website at www.lyell.com. About Lyell Immunopharma, Inc. Lyell is a late-stage cl
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lyell Immunopharma Inc.SCHEDULE 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
- PRLyell Immunopharma Announces Participation in May Investor ConferencesSOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the following investor conferences: H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026, in New York City, New York; fireside chat at 11:00 am Eastern Time2026 Stifel Virtual Targeted Oncology Forum on Wednesday, May 20, 2026; fireside chat at 4:00 pm Eastern Time A live webcast of each fireside chat can be accessed through the Investors
- SECSEC Form 10-Q filed by Lyell Immunopharma Inc.10-Q - Lyell Immunopharma, Inc. (0001806952) (Filer)
- SECLyell Immunopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
- PRLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in 2027PiNACLE-H2H, a first of its kind Phase 3 clinical trial evaluating ronde-cel head-to-head against standard-of-care CD19 CAR T-cell therapies in the LBCL second-line setting, commenced patient dosingPhase 1 clinical trial of LYL273 continues to enroll patients with metastatic colorectal cancer, with commencement of patient dosing at Dose Level 3Closed second $50 million tranche of $100 million private placement at $25.61 per share, with approximately
- ANALYSTRobert W. Baird initiated coverage on Lyell Immunopharma with a new price targetRobert W. Baird initiated coverage of Lyell Immunopharma with a rating of Outperform and set a new price target of $49.00
- SECSEC Form DEFA14A filed by Lyell Immunopharma Inc.DEFA14A - Lyell Immunopharma, Inc. (0001806952) (Filer)
- SECSEC Form DEF 14A filed by Lyell Immunopharma Inc.DEF 14A - Lyell Immunopharma, Inc. (0001806952) (Filer)
LYEL FAQ
7 questionsWhat does Lyell Immunopharma Inc. do?
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial...Where does LYEL stock trade?
Lyell Immunopharma Inc. (LYEL) is listed on NASDAQ.What sector and industry is LYEL in?
Lyell Immunopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Lyell Immunopharma Inc. go public?
Lyell Immunopharma Inc. (LYEL) completed its IPO in 2021.What are analysts saying about LYEL?
Lyell Immunopharma Inc. has had 8 recent analyst actions on file. The most recent action was from Robert W. Baird: Outperform with a $4900.00 price target on 2026-05-01.What companies are similar to LYEL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare LYEL side-by-side with any of them on Quantisnow.How can I track LYEL on Quantisnow?
Quantisnow aggregates Lyell Immunopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LYEL to receive live email and push alerts on every new disclosure.